

Publications COL 2020

Les 181 publications 2020 (26 rang A et 61 rang B) témoignent bien du dynamisme et de la grande diversité de la recherche au Centre Oscar Lambret, avec la valorisation de travaux en oncologie médicale, radiothérapie et radiophysique, chirurgie carcinologique, méthodologie des essais cliniques, biologie du cancer, mais aussi sciences humaines et sociales.

Publications 2020 à l'initiative des médecins et scientifiques du COL

Thématique Radiothérapie et Radiophysique (20 articles)

Bataille B, Escande A, Le Tinier F, Parent A, Bogart E, Collinet P, Bresson L, Narducci F, Leblanc E, Lemaire AS, Taieb S, Lartigau E, Mirabel X, Cordoba A. Outcomes of pre-operative brachytherapy followed by hysterectomy for early cervical cancer. *Int J Gynecol Cancer*. 2020 Feb;30(2):181-186.

Biston MC, Chiavassa S, Grégoire V, Thariat J, Lacornerie T. Time of PTV is ending, robust optimization comes next. *Cancer Radiother*. 2020 Oct;24(6-7):676-686.

Escande A, Khettab M, Bockel S, Dumas I, Schernberg A, Gouy S, Morice P, Pautier P, Deutsch E, Haie-Meder C, Chargari C. Interaction between the Number of Chemotherapy Cycles and Brachytherapy Dose/Volume Parameters in Locally Advanced Cervical Cancer Patients. *J Clin Med*. 2020 Jun 1;9(6):1653.

Jacob J, Reyns N, Valéry CA, Feuvret L, Simon JM, Mazon JJ, Jenny C, Cuttat M, Maingon P, Pasquier D. Radiotherapy of non-tumoral refractory neurological pathologies. *Cancer Radiother*. 2020 Oct;24(6-7):523-533.

Tonneau M, Elkrief A, Pasquier D, Paz Del Socorro T, Chamailard M, Bahig H, Routy B. The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: A systematic review. *Radiother Oncol*. 2020 Nov 1;156:1-9.

Jacob J, Reyns N, Valéry CA, Feuvret L, Simon JM, Mazon JJ, Jenny C, Cuttat M, Maingon P, Pasquier D. Radiotherapy of non-tumoral refractory neurological pathologies. *Cancer Radiother*. 2020 Oct;24(6-7):523-533.

Chevalier B, Pasquier D, Lartigau EF, Chargari C, Schernberg A, Jannin A, Mirabel X, Vantyghem MC, Escande A. Metformin: (future) best friend of the radiation oncologist? *Radiother Oncol*. 2020 Oct;151:95-105.

Latorzeff I, Sargos P, Créhange G, Belkacémi Y, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D. Indications et perspectives de l'hormonothérapie des cancers de prostate à haut risque [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]. *Cancer Radiother*. 2020 Apr;24(2):143-152.

Latorzeff I, Sargos P, Créhange G, Belkacémi Y, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D. Indications et perspectives

de l'hormonothérapie des cancers de prostate à haut risque [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]. *Cancer Radiother.* 2020 Apr;24(2):143-152.

Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, Bogart E, Le Deley MC, Steen V, Lacornerie T, Peiffert D, Mirabel X. Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial. *Int J Radiat Oncol Biol Phys.* 2020 May 1;107(1):116-125.

Wagner A, Brou Boni K, Rault E, Crop F, Lacornerie T, Van Gestel D, Reynaert N. Integration of the M6 Cyberknife in the Moderato Monte Carlo platform and prediction of beam parameters using machine learning. *Phys Med.* 2020 Feb;70:123-132.

Brou Boni KND, Klein J, Vanquin L, Wagner A, Lacornerie T, Pasquier D, Reynaert N. MR to CT synthesis with multicenter data in the pelvic area using a conditional generative adversarial network. *Phys Med Biol.* 2020 Apr 2;65(7):075002.

Dworczak M, Le Deley MC, Adenis A, Piessen G, Lartigau É, Mirabel X, Lacornerie T, Pasquier D. Facteurs dosimétriques liés aux complications pulmonaires postopératoires dans les cancers de l'œsophage localement avancés traités par radiochimiothérapie préopératoire : revue de la littérature [Dosimetric factors related to postoperative pulmonary complications in locally advanced esophageal cancers treated with preoperative chemoradiotherapy: Literature review]. *Bull Cancer.* 2020 Oct;107(10):982-990.

Pasquier D, Mouttet Audouard R, Martinage G, Lacornerie T, Mirabel X, Lartigau E. Place et modalités de l'irradiation postopératoire dans la prise en charge des métastases cérébrales [Place and modalities of postoperative radiotherapy in the management of cerebral metastases]. *Cancer Radiother.* 2020 Oct;24(6-7):477-481.

Plouvier SD, Bonnal JL, Machuron F, Colin P, Vankemmel O, Leroy X, Duhamel A, Villers A, Saint F, Pasquier D. Impact of age on bladder cancer management practices: a general population study. *Acta Oncol.* 2020 Apr;59(4):462-466.

Bataille B, Escande A, Le Tinier F, Parent A, Bogart E, Collinet P, Bresson L, Narducci F, Leblanc E, Lemaire AS, Taieb S, Lartigau E, Mirabel X, Cordoba A. Outcomes of pre-operative brachytherapy followed by hysterectomy for early cervical cancer. *Int J Gynecol Cancer.* 2020 Feb;30(2):181-186.

Bataille B, Raoudha B, Le Tinier F, Basson L, Escande A, Langin H, Tresch E, Crop F, Darloy F, Carlier D, Lartigau E, Pasquier D. Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer. *Cancers (Basel).* 2020 Dec 20;12(12):3852.

Fessart E, Mouttet Audouard R, Le Tinier F, Coche-Dequeant B, Lacornerie T, Tresch E, Scherpereel A, Lartigau E, Mirabel X, Pasquier D. Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series. *Sci Rep.* 2020 Jul 8;10(1):11201.

Pasquier D, Peiffert D, Nickers P, Maingon P, Pommier P, Lacornerie T, Martinage G, Tresch E, Lartigau E. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial. *Int J Radiat Oncol Biol Phys.* 2020 Jan 1;106(1):116-123.

Chevalier B, Pasquier D, Lartigau EF, Chargari C, Schernberg A, Jannin A, Mirabel X, Vantuyghem MC, Escande A. Metformin: (future) best friend of the radiation oncologist? *Radiother Oncol.* 2020 Oct;151:95-105.

Thématique Sarcome et Tumeurs rares (10 articles)

Cren PY, Lebellec L, Ryckewaert T, Penel N. Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials. *Front Oncol.* 2020 Nov 24;10:594445.

Penel N, Lebellec L, Blay JY, Robin YM. Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies. *Crit Rev Oncol Hematol.* 2020 Jun;150:102960.

Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzi E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol.* 2016 Dec;17(12):1732-1742.

Lebellec L, Defachelles AS, Cren PY, Penel N. Maintenance therapy and drug holiday in sarcoma patients: systematic review. *Acta Oncol.* 2020 Sep;59(9):1084-1090.

Penel N, Ryckewaert T, Orbach D. Traitements systémiques des fibromatoses agressives chez l'adulte et l'enfant : niveau de preuve et questions en suspens [Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions]. *Bull Cancer.* 2020 Mar;107(3):375-380.

Penel N, Orbach D. Les desmoïdes de l'enfant et de l'adulte : de la chirurgie radicale vers une adaptation thérapeutique moléculaire [Desmoid type fibromatosis, from radical excision to molecular extirpation]. *Bull Cancer.* 2020 Mar;107(3):344-345.

Brodowicz T, Liegl-Atzwanger B, Penel N, Mir O, Blay JY, Kashofer K, Le Cesne A, Decoupigny E, Wallet J, Hamacher R, Deley ML. Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. *Cancers (Basel).* 2020 Dec 12;12(12):3746.

Lottin M, Escande A, Peyre M, Sevestre H, Maurage CA, Chauffert B, Penel N. Quoi de neuf dans la prise en charge des tumeurs fibreuses solitaires/hémangiopéricytomes des méninges ? [What's new in the management of meningeal solitary fibrous tumor/hemangiopericytoma?]. *Bull Cancer.* 2020 Dec;107(12):1260-1273.

Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T; GCO-002 CACOVID-19 collaborators/investigators. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on

anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). *Eur J Cancer*. 2020 Dec;141:62-81.

le Guevelou J, Debaigt C, Saada-Bouzig E, Viotti J, Khalladi N, Thibouw D, Penel N, Sunyach MP, Moureau-Zabotto L, Benchalal M, Veresezan O, Ducassou A, le Pechoux C, Jolnerovski M, Bazille C, Vaur D, Escande A, Serre R, Lovera C, Thariat J. Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREO-SARC trial protocol. *BMJ Open*. 2020 Sep 23;10(9):e038391.

Thématique Cancérologie Générale (7 articles)

Ghysel V, Tresch E, Marliot G, Nicot R, Lambert M, Carbonnelle G, Lartigau E, Lefebvre G. Évaluation des interactions médicamenteuses chez des patients traités pour un cancer pulmonaire ou digestif [Evaluation of drug interactions in patients treated for a lung or digestive cancer]. *Bull Cancer*. 2020 Nov;107(11):1108-1117.

Jafari M, Schneider-Bordat L, Hersant B. Biological mesh used to repair perineal hernias following abdominoperineal resection for anorectal cancer. *Ann Chir Plast Esthet*. 2020 Jul;65(4):e15-e21.

Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, Awada A, Borel C, Ojalvo LS, Helwig C, Rolfe PA, Gulley JL, Penel N. Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. *J Immunother Cancer*. 2020 Jul;8(2):e000664.

Turpin A, Girard E, Baillet C, Pasquier D, Olivier J, Villers A, Puech P, Penel N. Imaging for Metastasis in Prostate Cancer: A Review of the Literature. *Front Oncol*. 2020 Jan 31;10:55.

Makhloufi S, Turpin A, El Amrani M, André T, Truant S, Bachet JB, Vernerey D, Hebbar M. Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. *Ann Surg Oncol*. 2020 Mar;27(3):877-885.

Bouras AF, Liddo G, Marx-Deseure A, Leroy A, Decanter G. Accessible laparoscopic liver resection performed in low volume centers: Is it time for democratization? *J Visc Surg*. 2020 Jun;157(3):193-197.

Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. *JAMA Oncol*. 2020 Oct 1;6(11):1-7.

Thématiques Sénologie (6 articles)

Le Rhun E, Wallet J, Mailliez A, Le Deley MC, Rodrigues I, Boulanger T, Lorgis V, Barrière J, Robin YM, Weller M, Bonnetterre J. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. *Neuro Oncol*. 2020 Apr 15;22(4):524-538.

Saadeh R, Naga N, Mesdag V, Régis C. Unusual burn injury to a deep inferior epigastric perforator flap reconstructed breast. *Breast J.* 2020 Mar;26(3):526.

Jacot W, Arnaud A, Jarlier M, Lefeuvre-Plesse C, Dalivoust P, Senesse P, Azzedine A, Tredan O, Sadot-Lebouvier S, Mas S, Carayol M, Bleuse JP, Gourgou S, Janiszewski C, Launay S, D'Hondt V, Lauridant G, Grenier J, Romieu G, Ninot G, Vanlemmens L. Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial. *Nutrients.* 2020 Oct 9;12(10):3081.

Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, Desmedt C, Larsimont D, Park M, Rothé F, Stagg J, Sotiriou C. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. *J Natl Cancer Inst.* 2020 Jul 1;112(7):708-719.

Debry L, Luu J, Boulanger L, Le Deley MC, Régis C. Reducing the seroma volume by quilting suture after breast reconstruction with a latissimus dorsi flap: Single institutional experience. *Bull Cancer.* 2020 May;107(5):543-550.

Gougis P, Carton M, Tchokothe C, Campone M, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Bachelot T, Hennequin A, Perrin C, Gonçalves A, Uwer L, Eymard JC, Petit T, Mouret-Reynier MA, Chamorey E, Simon G, Saghatchian M, Cailliot C, Le Tourneau C. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database. *Breast.* 2020 Feb;49:17-24.

Thématique Cancérologie Pédiatrique (3 articles)

Sudour-Bonnange H, Coulomb-Lherminé A, Fantoni JC, Escande A, Brisse HJ, Thebaud E, Verschuur A. Standard of care for adult Wilms tumor? From adult urologist to pediatric oncologist. A retrospective review. *Bull Cancer.* 2020 Oct 28:S0007-4551(20)30405-7.

Lervat C, Vanlemmens L, Bondil P, Jacquot J, Scotté F, Gofti-Laroche L. Les soins de support pour améliorer l'accompagnement personnalisé des patients [Oncologic supportive care for a personalized support of all patients]. *Bull Cancer.* 2020 Oct 20:S0007-4551(20)30371-4.

Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, Burke A, Horibe K, Nakazawa A, Wrobel G, Mann G, Csóka M, Uyttebroeck A, Fernández-Delgado Cerdá RF, Beishuizen A, Mellgren K, Burkhardt B, Klapper W, Turner SD, D'Amore ESG, Lamant L, Reiter A, Woessmann W, Brugières L, Pilon MPOBOTEIFCNL. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. *Cancers (Basel).* 2020 Sep 24;12(10):2747.

Thématique Cancérologie Gynécologique (2 articles)

Narducci F, Bogart E, Hebert T, Gauthier T, Collinet P, Classe JM, Lecuru F, Delest A, Motton S, Conri V, Ferrer C, Marchal F, Ferron G, Probst A, They J, Le Deley MC, Lefebvre D, Francon D, Leblanc E, Lambaudie E. Severe perioperative morbidity after robot-assisted versus conventional laparoscopy in gynecologic oncology: Results of the randomized ROBOGYN-1004 trial. *Gynecol Oncol*. 2020 Aug;158(2):382-389.

Kerbage Y, Kakkos A, Kridelka F, Lambaudie E, Bats AS, Hébert T, Goffin F, Wallet J, Leblanc E, Hudry D, Narducci F. Lomboaortic Lymphadenectomy in Gynecological Oncology: Laparotomy, Laparoscopy or Robot-Assisted Laparoscopy? *Ann Surg Oncol*. 2020 Oct;27(10):3891-3897.

Thématique Soins Palliatifs (3 articles)

Gamblin V, Berry V, Tresch-Bruneel E, Reich M, Da Silva A, Villet S, Penel N, Prod'Homme C. Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control. *BMC Palliat Care*. 2020 Jun 19;19(1):85.

Saudemont G, Prod'Homme C, Da Silva A, Villet S, Reich M, Penel N, Gamblin V. The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. *BMC Palliat Care*. 2020 Apr 22;19(1):56.

Reich M, Bondenet X, Rambaud L, Ait-Kaci F, Sedda AL, Da Silva A, Villet S, Gamblin V. Refractory psycho-existential distress and continuous deep sedation until death in palliative care: The French perspective. *Palliat Support Care*. 2020 Aug;18(4):486-494.

Thématique Imagerie médicale (1 article)

Ben Haj Amor M, Ploton L, Ceugnart L, Taïeb S. Imagerie par résonance magnétique des tumeurs desmoïdes : critères d'évaluations actuels [Magnetic resonance imaging of desmoid-type fibromatosis: Current evaluation criteria]. *Bull Cancer*. 2020 Mar;107(3):359-363.

Autres publications

Cren PY, Marliot G, Pannier D, Penel N, Strobbe G. Symptomatic acute hypotension associated with high-dose dacarbazine. *Melanoma Res*. 2020 Aug;30(4):426-428.

Cren PY, Bertrand N, Le Deley MC, Génin M, Mortier L, Odou P, Penel N, Chazard E. Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI). *Oncoimmunology*. 2020 Nov 22;9(1):1846914.

Strobbe G, Pannier D, Sakji I, Villain A, Feutry F, Marliot G. Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: A case report. *J Oncol Pharm Pract*. 2020 Oct;26(7):1743-1749.

Publications associant le COL

Radiothérapie et radiophysique (23 publications)

Largent A, Marage L, Gicquiau I, Nunes JC, Reynaert N, Castelli J, Chajon E, Acosta O, Gambarota G, de Crevoisier R, Saint-Jalmes H. Head-and-Neck MRI-only radiotherapy treatment planning: From acquisition in treatment position to pseudo-CT generation. *Cancer Radiother.* 2020 Jul;24(4):288-297.

de Jong EEC, Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Milder M, Møller DS, Nyeng TB, Tanadini-Lang S, Lartigau E, Lacornerie T, Senan S, Verbakel W, Verellen D, De Kerf G, Hurkmans C. Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. *Radiother Oncol.* 2020 Jan;142:217-223.

Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelet J, Rivera S, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Gonçalves A, Jankowski C, De La Motte Rouge T, Pouget N, De La Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Courtinard C, Filleron T, Robain M, Dalenc F. Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis. *Radiother Oncol.* 2020 Apr;145:109-116.

Hannoun-Lévi JM, Chand MÈ, Blanchard P, Chargari C, Escande A, Pierrat N, Pommier P, Peiffert D. Curiethérapie en France en 2020 : synthèse et perspectives du Groupe curiethérapie de la Société française de radiothérapie oncologique [Brachytherapy in France in 2020: State of the art and perspectives from the Groupe curiethérapie de la SFRO]. *Cancer Radiother.* 2020 Dec;24(8):876-881.

Fogliata A, Cayez R, Garcia R, Khamphan C, Reggiori G, Scorsetti M, Cozzi L. Technical Note: Flattening filter free beam from Halcyon linac: Evaluation of the profile parameters for quality assurance. *Med Phys.* 2020 Aug;47(8):3669-3674.

Carrie C, Kieffer V, Figarella-Branger D, Masliah-Planchon J, Bolle S, Bernier V, Laprie A, Supiot S, Leseur J, Habrand JL, Alapetite C, Kerr C, Dufour C, Claude L, Chapet S, Huchet A, Bondiau PY, Escande A, Truc G, Nguyen TD, Pasteuris C, Vigneron C, Muracciole X, Bourdeaut F, Appay R, Dubray B, Colin C, Ferlay C, Dussart S, Chabaud S, Padovani L; French Group of Pediatric Radiotherapy (GFRP); French Society of Pediatric Cancers (SFCE). Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups. *Int J Radiat Oncol Biol Phys.* 2020 Dec 1;108(5):1204-1217.

Chargari C, Renard S, Espenel S, Escande A, Buchheit I, Ducassou A, Peiffert D, Hannoun-Lévi JM. La radiothérapie stéréotaxique peut-elle remplacer la curiethérapie pour les cancers du col utérin localement évolués ? Positionnement de la Société française de radiothérapie oncologique [Can stereotactic body radiotherapy replace brachytherapy for locally advanced cervical cancer? French society for radiation oncology statement]. *Cancer Radiother.* 2020 Oct;24(6-7):706-713.

Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche S, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihou M, Soulié M, Richaud P. GETUG-AFU 17 : étude de phase III randomisée comparant la radiothérapie adjuvante à la radiothérapie de rattrapage précoce, combinées à l'hormonothérapie courte, pour les patients

présentant un cancer de la prostate traité par prostatectomie radicale. *Prog Urol.* 2020 Nov;30(13):733-734.

Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche MS, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihoum M, Soulié M, Richaud P. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. *Lancet Oncol.* 2020 Oct;21(10):1341-1352.

Krengli M, Cena T, Zilli T, Jereczek-Fossa BA, De Bari B, Villa Freixa S, Kaanders JHAM, Torrente S, Pasquier D, Sole CV, Lutsyk M, Dinckbas FO, Habboush Y, Fariselli L, Dragan T, Baumert BG, Khanfir K, Ugurluer G, Thariat J. Radiotherapy in the treatment of extracranial hemangiopericytoma/solitary fibrous tumor: Study from the Rare Cancer Network. *Radiother Oncol.* 2020 Mar;144:114-120.

Beudelot C, Bayart E, Thariat J, Bourgier C, Denis F, Hatt M, Pasquier D, Verry C, Deutsch É, Levy A. Oncologie-radiothérapie horizon 2030 : du microbiote au laser plasma [Radiation-oncology horizon 2030: From microbiota to plasma laser]. *Cancer Radiother.* 2020 Oct;24(6-7):744-750.

Lieverse RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, Hadrup SR, Dingemans AC, Hendriks LEL, Eckert F, Hiley C, Dooms C, Lievens Y, de Jong MC, Bussink J, Geets X, Valentini V, Elia G, Neri D, Billiet C, Abdollahi A, Pasquier D, Boisselier P, Yaromina A, De Ruyscher D, Dubois LJ, Lambin P. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. *BMC Cancer.* 2020 Jun 15;20(1):557.

Claude L, Morelle M, Mahé MA, Pasquier D, Boisselier P, Bondiau PY, Touboul E, Peignaux-Casasnovas K, Martel-Lafay I, Gassa F, Perrier L, Dussart S, Beckendorf V. A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study. *Br J Radiol.* 2020 Dec 1;93(1116):20200256.

Claude L, Morelle M, Mahé MA, Pasquier D, Boisselier P, Bondiau PY, Touboul E, Peignaux-Casasnovas K, Martel-Lafay I, Gassa F, Perrier L, Dussart S, Beckendorf V. A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study. *Br J Radiol.* 2020 Dec 1;93(1116):20200256.

Hannoun-Levi JM, Gal J, Van Limbergen E, Chand ME, Schiappa R, Smanyko V, Kauer-Domer D, Pasquier D, Lemanski C, Racadot S, Houvenaeghel G, Guix B, Belliere-Calandry A, Loessl K, Polat B, Gutierrez C, Galalae R, Polgar C, Strnad V. Salvage mastectomy versus second conservative treatment for second ipsilateral breast tumor event: A propensity score-matched cohort analysis of the database. *Int J Radiat Oncol Biol Phys.* 2020 Dec 28;S0360-3016(20)34722-2.

Belkacemi Y, Latorzeff I, Hasbini A, Coraggio G, Pasquier D, Toledano A, Hennequin C, Bossi A, Chapet O, Crehange G, Guerif S, Duberge T, Allouache N, Clavere P, Gross E, Supiot S, Azria D, Bolla M, Sargos P. Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group. *Cancer Radiother.* 2020 Dec;24(8):892-897.

Milhem C, Moralès O, Ingelaere C, Pasquier D, Mordon S, Mortier L, Mirabel X, Delhem N. Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient. *Int J Mol Sci.* 2020 Sep 15;21(18):6772.

Aznar MC, Bacchus C, Coppes RP, Deutsch E, Georg D, Haustermans K, Hoskin P, Krause M, Lartigau EF, Löck S, Offersen B, Overgaard J, Thwaites DI, van der Kogel AJ, van der Heide UA, Valentini V, Baumann M. Radiation oncology in the new virtual and digital era. *Radiother Oncol*. 2020 Dec 30;S0167-8140(20)31258-5.

Giraud P, Giraud P, Nicolas E, Boisselier P, Alfonsi M, Rives M, Bardet E, Calugaru V, Noel G, Chajon E, Pommier P, Morelle M, Perrier L, Liem X, Burgun A, Bibault JE. Interpretable Machine Learning Model for Locoregional Relapse Prediction in Oropharyngeal Cancers. *Cancers (Basel)*. 2020 Dec 28;13(1):57.

Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, Lafond C, Miroir J, Liem X, Rolland F, Even C, Nguyen F, Saada E, Maillard A, Colin-Bataillou N, Thariat J, Guigay J, Bourhis J. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). *Eur J Cancer*. 2020 Dec;141:21-29.

Giraud P, Lerouge D, Latorzeff I, Mirabel X, Dohan A, Mordant P, Barry de Longchamps N. Radiothérapie stéréotaxique des tumeurs primitives extracrâniennes [Stereotaxic radiotherapy of primary extracranial tumors]. *Cancer Radiother*. 2020 Oct;24(6-7):513-522. Erratum in: *Cancer Radiother*. 2020 Dec;24(8):898.

Le Guevelou J, Bastit V, Marcy PY, Lasne-Cardon A, Guzène L, Gerard M, Larnaudie A, Coutte A, Beddok A, Calugaru V, Johnson A, Gery B, Liem X, Pointreau Y, Bourhis J, Thariat J; GORTEC. Flap delineation guidelines in postoperative head and neck radiation therapy for head and neck cancers. *Radiother Oncol*. 2020 Oct;151:256-265.

Schernberg A, Kumar T, Achkar S, Espenel S, Bockel S, Majer M, Escande A, Mignot F, Annede P, Monnier L, Huguet F, Chargari C. Incorporating Magnetic Resonance Imaging (MRI) Based Radiation Therapy Response Prediction into Clinical Practice for Locally Advanced Cervical Cancer Patients. *Semin Radiat Oncol*. 2020 Oct;30(4):291-299.

Oncologie pédiatrique (23 publications)

Rouger-Gaudichon J, Thébaud E, Félix A, Phulpin A, Paillard C, Alimi A, Brethon B, Gouache E, Raimbault S, de Berranger E, Poirée M, Bouttefroy S, André N, Gandemer V, On Behalf Of Société Française de Lutte Contre Les Cancers Et Leucémies de l'Enfant Et de L'adolescent Sfce. Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report from the French Society of Pediatric Oncology. *Cancers (Basel)*. 2020 Nov 17;12(11):3398.

Rodriguez Gutierrez D, Jones C, Varlet P, Mackay A, Warren D, Warmuth-Metz M, Aliaga ES, Calmon R, Hargrave DR, Cañete A, Massimino M, Azizi AA, Le Deley MC, Saran F, Rousseau RF, Zahlmann G, Garcia J, Vassal G, Grill J, Morgan PS, Jaspan T. Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial. *Clin Cancer Res*. 2020 Apr 15;26(8):1856-1865.

Marec-Berard P, Dalban C, Gaspar N, Brugieres L, Gentet JC, Lervat C, Corradini N, Castex MP, Schmitt C, Pacquement H, Tabone MD, Brahmi M, Metzger S, Blay JY, Pérol D; OSII Thiotepa study group of the French Society of Pediatric Cancer - La Société Française des Cancers de l'Enfant (SFCE) and the French Sarcoma Group—Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) Networks. A multicentric

randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma. *Eur J Cancer*. 2020 Jan;125:58-68.

Dumont B, Fresneau B, Claude L, Defachelles AS, Couloigner V, Puget S, Brisse HJ, Fréneaux P, Lacour B, Orbach D. Pattern of loco-regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution. *Pediatr Blood Cancer*. 2020 Apr;67(4):e28154.

Azizi AA, Walker DA, Liu JF, Sehested A, Jaspan T, Pemp B, Simmons I, Ferner R, Grill J, Hargrave D, Driever PH, Evans DG, Opocher E; SIOPE NF1 OPG Nottingham, UK, Workshop 2014. NF1 optic pathway glioma. Analysing risk factors for visual outcome and indications to treat. *Neuro Oncol*. 2020 Jul 6:noaa153.

Hol JA, Jongmans MCJ, Sudour-Bonnange H, Ramírez-Villar GL, Chowdhury T, Rechnitzer C, Pal N, Schleiermacher G, Karow A, Kuiper RP, de Camargo B, Avcin S, Redzic D, Wachtel A, Segers H, Vujanic GM, van Tinteren H, Bergeron C, Pritchard-Jones K, Graf N, van den Heuvel-Eibrink MM; International Society of Pediatric Oncology Renal Tumor Study Group (SIOP-RTSG). Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience. *Cancer*. 2020 Nov 4.

de Tersant M, Généré L, Freyçon C, Villebasse S, Abbas R, Barlier A, Bodet D, Corradini N, Defachelles AS, Entz-Werle N, Fouquet C, Galmiche L, Gandemer V, Lacour B, Mansuy L, Orbach D, Pluchart C, Réguerre Y, Rigaud C, Sarnacki S, Sirvent N, Stephan JL, Thebaud E, Gimenez-Roqueplo AP, Brugières L. Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE). *J Endocr Soc*. 2020 Apr 3;4(5):bvaa039.

Allodji RS, Tucker MA, Hawkins MM, Le Deley MC, Veres C, Weathers R, Howell R, Winter D, Haddy N, Rubino C, Diallo I, Little MP, Morton LM, de Vathaire F. Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis. *Int J Cancer*. 2020 Oct 26.

Jouglar E, Escande A, Martin V, Demoor-Goldschmidt C, Carrie C, Claude L, Bernier-Chastagner V. Impact de l'âge et radiothérapie : points clés chez les AJA [Influence of age on indications and modalities of radiation therapy: What to keep in mind for adolescents and young adults?]. *Bull Cancer*. 2020 Oct 10:S0007-4551(20)30380-5.

Walker DA, Azizi AA, Liu JF, Sehested A, Jaspan T, Pemp B, Simmons I, Ferner R, Grill J, Hargrave D, Driever PH, Evans DG, Opocher E; SIOPE NF1 OPG Nottingham, UK, Workshop 2014. Regarding "Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma". *Neurooncol Pract*. 2020 Aug 17;7(5):572-573.

Pondrom M, Bougeard G, Karanian M, Bonneau-Lagacherie J, Boulanger C, Boutroux H, Briandet C, Chevreau C, Corradini N, Coze C, Defachelles AS, Galmiche-Roland L, Orbach D, Piguet C, Scoazec JY, Vérité C, Willems M, Frebourg T, Minard V, Brugières L. Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience. *Pediatr Blood Cancer*. 2020 Sep;67(9):e28486.

Vairy S, Le Teuff G, Bautista F, De Carli E, Bertozzi AI, Pagnier A, Fouyssac F, Nysom K, Aerts I, Leblond P, Millot F, Berger C, Canale S, Paci A, Poinsignon V, Chevance A, Ezzalfani M, Vidaud D, Di Giannatale A, Hladun-Alvaro R, Petit FM, Vassal G, Geoerger B, Le Deley MC, Grill J. Phase I study of vinblastine in

combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma. *Neurooncol Adv.* 2020 Jun 9;2(1):vdaa075.

Rios P, Bauer H, Schleiermacher G, Pasqualini C, Boulanger C, Thebaud E, Gandemer V, Pellier I, Verschuur A, Sudour-Bonnange H, Coulomb-l'Hermine A, Spiegel A, Notz-Carrere A, Bergeron C, Orsi L, Lacour B, Clavel J. Environmental exposures related to parental habits in the perinatal period and the risk of Wilms' tumor in children. *Cancer Epidemiol.* 2020 Jun;66:101706.

Del Baldo G, Abbas R, Woessmann W, Horibe K, Pillon M, Burke A, Beishuizen A, Rigaud C, Le Deley MC, Lamant L, Brugières L. Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma. *Br J Haematol.* 2020 Jul 9. doi: 10.1111/bjh.16755.

Le Teuff G, Castaneda-Heredia A, Dufour C, Jaspan T, Calmon R, Devos A, McHugh K, Leblond P, Frappaz D, Aerts I, Zwaan CM, Ducassou S, Chastagner P, Verschuur A, Corradini N, Casanova M, Rubie H, Riccardi R, Le Deley MC, Vassal G, Geoerger B; European consortium Innovative Therapies for Children with Cancer (ITCC). Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. *Pediatr Blood Cancer.* 2020 Jan;67(1):e28032.

Varlet P, Le Teuff G, Le Deley MC, Giangaspero F, Haberler C, Jacques TS, Figarella-Branger D, Pietsch T, Andreiuolo F, Deroulers C, Jaspan T, Jones C, Grill J. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. *Neuro Oncol.* 2020 Jan 11;22(1):116-127.

Surun A, Varlet P, Brugières L, Lacour B, Faure-Contier C, Leblond P, Bertozzi-Salomon AI, Berger C, André N, Sariban E, Raimbault S, Prieur F, Desseigne F, Zattara H, Guimbaud R, Polivka M, Delisle MB, Vasiljevic A, Maurage CA, Figarella-Branger D, Coulet F, Guerrini-Rousseau L, Alapetite C, Dufour C, Colas C, Doz F, Bourdeaut F. Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas. *Neuro Oncol.* 2020 Jan 11;22(1):128-138.

Liné A, Sudour-Bonnange H, Languillat-Fouquet V, Brisse H, Irtan S, Verschuur A, Sarnacki S, Thébaud E, Coulomb-L'Hermine A, Notz-Carrère A, Michon J, Tabone MD, Boulanger C, Pellier I, Freycon C, Audry G, Dijoud F, Morelle M, Bergeron C, Pasqualini C. Liver metastasis at diagnosis in children with nephroblastoma enrolled in SIOP2001 protocol: A French multicentric study. *Pediatr Blood Cancer.* 2020 Jun;67(6):e28201.

Duhil de Bénazé G, Vigan M, Corradini N, Minard-Colin V, Marie-Cardine A, Verite C, Defachelles AS, Thebaud E, Castex MP, Sirvent N, Bodet D, Mansuy L, Rome A, Petit A, Plantaz D, Jourdain A, Mary P, Carton M, Orbach D. Functional analysis of young patients with desmoid-type fibromatosis: Initial surveillance does not jeopardize long term quality of life. *Eur J Surg Oncol.* 2020 Jul;46(7):1294-1300.

Butel T, Karanian M, Pierron G, Orbach D, Ranchere D, Cozic N, Galmiche L, Coulomb A, Corradini N, Lacour B, Proust S, Guerin F, Boutroux H, Rome A, Mansuy L, Vérité C, Defachelles AS, Tirode F, Minard-Colin V. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee. *Cancer Med.* 2020 Apr;9(8):2698-2709.

Vaarwerk B, Mallebranche C, Affinita MC, van der Lee JH, Ferrari A, Chisholm JC, Defachelles AS, De Salvo GL, Corradini N, Minard-Colin V, Morosi C, Brisse HJ, McHugh K, Bisogno G, van Rijn RR, Orbach

D, Merks JHM. Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. *Cancer*. 2020 Feb 15;126(4):823-831.

Marec-Berard P, Laurence V, Ocean BV, Ray-Coquard I, Linassier C, Corradini N, Collard O, Chaigneau L, Cupissol D, Kerbrat P, Saada-Bouزيد E, Delcambre C, Gouin F, Guillemet C, Jimenez M, Lervat C, Gaspar N, Le Deley MC, Brugieres L, Piperno-Neumann S. Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years. *J Adolesc Young Adult Oncol*. 2020 Apr;9(2):172-182.

Picard C, Faure-Contier C, Leblond P, Brugières L, Thomas-Teinturier C, Hameury F, Defachelles AS, Verschuur A, Brisse HJ, Sarnacki S, Dijoud F, Reguerre Y, Chastagner P, Carton M, Orbach D. Exploring heterogeneity of adrenal cortical tumors in children: The French pediatric rare tumor group (Fracture) experience. *Pediatr Blood Cancer*. 2020 Feb;67(2):e28086.

Oncologie générale (16 publications)

Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. *Oncologist*. 2020 Nov;25(11):e1701-e1710.

Vishwanathan K, Sanchez-Simon I, Keam B, Penel N, de Miguel-Luken M, Weilert D, Mills A, Marotti M, Johnson M, Ravaud A. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. *Pharmacol Res Perspect*. 2020 Aug;8(4):e00613.

Denost Q, Solomon M, Tuech JJ, Ghouti L, Cotte E, Panis Y, Lelong B, Rouanet P, Faucheron JL, Jafari M, Lefevre JH, Rullier E, Heriot A, Austin K, Lee P, Brown W, Maillou-Martinaud H, Savel H, Quintard B, Broc G, Saillour-Glénisson F. International variation in managing locally advanced or recurrent rectal cancer: prospective benchmark analysis. *Br J Surg*. 2020 Dec;107(13):1846-1854

Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebutti-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. *BMC Cancer*. 2020 Apr 25;20(1):352.

Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, Bouche O, Di Fiore F, Chauvenet M, Perrier H, Evesque L, Laurent-Puig P, Emile JF, Bez J, Lepage C, Tougeron D. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. *Dig Liver Dis*. 2020 Dec 24:S1590-8658(20)31052-5.

Hammel P, Fabienne P, Mineur L, Metges JP, Andre T, De La Fouchardiere C, Louvet C, El Hajbi F, Faroux R, Guimbaud R, Tougeron D, Bouche O, Lecomte T, Rebuschung C, Tournigand C, Cros J, Kay R, Hamm A, Gupta A, Bachet JB, El Hariry I. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized

Phase IIb trial. *Eur J Cancer*. 2020 Jan;124:91-101. doi: 10.1016/j.ejca.2019.10.020. Epub 2019 Nov 21. Erratum in: *Eur J Cancer*. 2020 May;130:275-276.

Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. *J Thorac Oncol*. 2020 Apr;15(4):618-627.

Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Leuret T, Neuzillet Y, Penel N, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupert M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S. Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. *Clin Genitourin Cancer*. 2020 Aug;18(4):295-303.e3.

Gronchi A, Bonvalot S, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom HJ, van Coevorden F, Penel N, Kopp HG, Duffaud F, Goldstein D, Broto JM, Wardelmann E, Marréaud S, Smithers M, Le Cesne A, Zaffaroni F, Litière S, Blay JY, Casali PG. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. *JAMA Surg*. 2020 Jun 1;155(6):e200397.

Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C; Groupe Français de Pneumo-Cancérologie 01–13 investigators. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2020 Sep;21(9):1224-1233.

Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, Vernerey D, Borg C. Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. *Ther Adv Med Oncol*. 2020 Dec 4;12:1758835920975356.

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Gori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol*. 2020 Jan 1;38(1):1-10.

Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, de Chaisemartin C, Rivoire M, Trilling B, Jafari M, Portier G, Meunier B, Sieleznieff I, Bertrand M, Marchal F, Dubois A, Pocard M, Rullier A, Smith D, Frulio N, Frison E, Denost Q. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. *Lancet Gastroenterol Hepatol*. 2020 May;5(5):465-474.

Maillard M, Chevreau C, Le Louedec F, Cassou M, Delmas C, Gourdain L, Blay JY, Cupissol D, Bompas E, Italiano A, Isambert N, Delcambre-Lair C, Penel N, Bertucci F, Guillemet C, Plenecassagnes J, Foulon S, Chatelut É, Le Cesne A, Thomas F. Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. *Cancers (Basel)*. 2020 Dec 4;12(12):3647.

Chau I, Penel N, Soriano AO, Arkenau HT, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Bendell JC, Mi G, Gao L, McNeely SC, Oliveira JM, Ferry D, Herbst RS, Fuchs CS. Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. *Cancers (Basel)*. 2020 Oct 15;12(10):2985.

Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Mi G, Wang H, Rasmussen E, Ferry D, Chao BH, Paz-Ares L. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. *J Thorac Oncol*. 2020 Oct 15:S1556-0864(20)30809-1.

Sénologie (14 publications)

Cohen M, Benhaim S, Coudray AJ, Chauvet MP, Ribierre SG, Llorca FP, Faure C, Opinel P, Bertrand P, Detroyer J, Eisinger F, Lambaudie E, Dauplat MM, Charafe Jauffret E, Houvenaeghel G; Co-investigators. When to do surgical resection for atypical breast lesions: Results of a prospective cohort of 518 lesions. *Surg Oncol*. 2020 Sep;34:80-85.

Lange M, Hardy-Léger I, Licaj I, Pistilli B, Rigal O, Le Fel J, Lévy C, Capel A, Coutant C, Meyer J, Lerebours F, Petrucci J, Vanlemmens L, Brion M, Campone M, Soulié P, Blain M, Vaz-Luis I, Giffard B, Martin AL, Everhard S, André F, Dauchy S, Joly F. Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort Subgroup. *Cancer Epidemiol Biomarkers Prev*. 2020 Sep;29(9):1759-1766..

Dumas A, Vaz Luis I, Bovagnet T, El Mouhebb M, Di Meglio A, Pinto S, Charles C, Dauchy S, Delalogue S, Arveux P, Coutant C, Cottu P, Lesur A, Lerebours F, Tredan O, Vanlemmens L, Levy C, Lemonnier J, Mesleard C, Andre F, Menvielle G. Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). *J Clin Oncol*. 2020 Mar 1;38(7):734-743.

Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Courtinard C, Perol D, Robain M, Delalogue S. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. *Eur J Cancer*. 2020 Apr;129:60-70.

Di Meglio A, Michiels S, Jones LW, El-Mouhebb M, Ferreira AR, Martin E, Matias M, Lohmann AE, Joly F, Vanlemmens L, Everhard S, Martin AL, Lemonnier J, Arveux P, Cottu PH, Coutant C, Del Mastro L, Partridge AH, André F, Ligibel JA, Vaz-Luis I. Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. *Breast*. 2020 Aug;52:23-32.

Uzan C, Mazouni C, Rossoni C, De Korvin B, de Lara CT, Cohen M, Chabbert N, Zilberman S, Boussion V, Vincent Salomon A, Espie M, Coutant C, Marchal F, Salviat F, Boulanger L, Doutriaux-Dumoulin I, Jouve E, Mathelin C, de Saint Hilaire P, Mollard J, Balleyguier C, Joyon N, Triki ML, Delalogue S, Michiels S. Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions. *Ann Surg Oncol*. 2020 Sep 12.

Cutuli B, Lemanski C, De Lafontan B, Chauvet MP, De Lara CT, Mege A, Fric D, Richard-Molard M, Mazouni C, Cuvier C, Carre A, Kirova Y. Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients. *Clin Breast Cancer*. 2020 Apr;20(2):e164-e172.

Saleh K, Carton M, Dieras V, Heudel PE, Brain E, D'Hondt V, Mailliez A, Patsouris A, Mouret-Reynier MA, Goncalves A, Ferrero JM, Petit T, Emile G, Uwer L, Debled M, Dalenc F, Jouannaud C, Ladoire S, Leheurteur M, Cottu P, Veron L, Savignoni A, Courtinard C, Robain M, Delalogue S, Deluche E. Impact of body mass index on overall survival in patients with metastatic breast cancer. *Breast*. 2020 Dec 1;55:16-24.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study. *EClinicalMedicine*. 2020 Nov 4;28:100566.

Frasca M, Sabathe C, Delalogue S, Galvin A, Patsouris A, Levy C, Mouret-Reynier MA, Desmoulins I, Vanlemmens L, Bachelot T, Goncalves A, Perotin V, Uwer L, Frenel JS, Ferrero JM, Bouleuc C, Eymard JC, Dieras V, Leheurteur M, Petit T, Dalenc F, Jaffre A, Chevrot M, Courtinard C, Mathoulin-Pelissier S. Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016. *Eur J Cancer*. 2020 Sep;137:240-249.

Di Meglio A, Menvielle G, Dumas A, Gbenou A, Pinto S, Bovagnet T, Martin E, Ferreira AR, Vanlemmens L, Arsene O, Ibrahim M, Wassermann J, Martin AL, Lemonnier J, Del Mastro L, Jones LW, Partridge AH, Ligibel JA, Andre F, Michiels S, Vaz Luis I. Body weight and return to work among survivors of early-stage breast cancer. *ESMO Open*. 2020 Nov;5(6):e000908.

Pistilli B, Paci A, Ferreira AR, Di Meglio A, Poinsignon V, Bardet A, Menvielle G, Dumas A, Pinto S, Dauchy S, Fasse L, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Arveux P, Martin AL, Dima A, Lin NU, Partridge AH, Delalogue S, Michiels S, André F, Vaz-Luis I. Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. *J Clin Oncol*. 2020 Aug 20;38(24):2762-2772.

Hardy-Leger I, Charles C, Lange M, Joly F, Roux P, Capel A, Petrucci J, Rigal O, Le Fel J, Vanlemmens L, Everhard S, Martin AL, Vaz Luis I, Coutant C, Cottu P, Levy C, Lerebours F, Andre F, Licaj I, Dauchy S. Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohort. *Psychooncology*. 2020 Oct 14.

Frank S, Carton M, Dubot C, Campone M, Pistilli B, Dalenc F, Mailliez A, Levy C, D'Hondt V, Debled M, Vermeulin T, Coudert B, Perrin C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Patsouris A, Guesmia T, Bachelot T, Robain M, Cottu P. Impact of age at diagnosis of metastatic

breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. *Breast*. 2020 Aug;52:50-57.

Oncologie gynécologique (14 publications)

Chiva L, Zanagnolo V, Querleu D, Martin-Calvo N, Arévalo-Serrano J, Căpîlna ME, Fagotti A, Kucukmetin A, Mom C, Chakalova G, Aliyev S, Malzoni M, Narducci F, Arencibia O, Raspagliesi F, Toptas T, Cibula D, Kaidarova D, Meydanli MM, Tavares M, Golub D, Perrone AM, Poka R, Tsolakidis D, Vujić G, Jedryka MA, Zusterzeel PLM, Beltman JJ, Goffin F, Haidopoulos D, Haller H, Jach R, Yezhova I, Berlev I, Bernardino M, Bharathan R, Lanner M, Maenpaa MM, Sukhin V, Feron JG, Fruscio R, Kukk K, Ponce J, Minguez JA, Vázquez-Vicente D, Castellanos T, Chacon E, Alcazar JL; SUCCOR study Group. SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer. *Int J Gynecol Cancer*. 2020 Sep;30(9):1269-1277.

Vergote I, Magrina JF, Zanagnolo V, Magtibay PM, Butler K, Gil-Moreno A, Feijoo BD, Kimmig R, Canis M, Bourdel N, Ind T, Estape R, Persson J, Lim P, Coronado P, Ponce J, Lambaudie E, Van Gorp T, Maggioni A, Narducci F, Van Niewwenhuysen E, Van Trappen P. The LACC Trial and Minimally Invasive Surgery in Cervical Cancer. *J Minim Invasive Gynecol*. 2020 Feb;27(2):462-463.

Chevrot A, Pouget N, Bats AS, Huchon C, Guyon F, Chopin N, Rousset-Jablonski C, Beurrier F, Lambaudie E, Provansal M, Sabatier R, Heinemann M, Ngo C, Bonsang-Kitzis H, Lecuru F, Bailly E, Ferron G, Cornou C, Lardin E, Leblanc E, Philip CA, Ray-Coquard I, Hequet D. Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group. *Gynecol Oncol*. 2020 Apr;157(1):29-35.

Angeles MA, Mallet E, Rouanet P, Cabarrou B, Méeus P, Lambaudie E, Foucher F, Narducci F, Loaec C, Gouy S, Guyon F, Marchal F, Gladiéff L, Martínez-Gómez C, Migliorelli F, Martinez A, Ferron G. Comparison of postoperative complications and quality of life between patients undergoing continent versus non-continent urinary diversion after pelvic exenteration for gynecologic malignancies. *Int J Gynecol Cancer*. 2020 Feb;30(2):233-240.

Sawan D, Bosc R, La Padula S, Leblanc E, Narducci F, Touboul C, Meningaud JP, Hersant B. Immediate vaginal reconstruction following pelvic exenteration using the pedicled vertical Deep Inferior Epigastric Perforator (DIEP) flap: A technical note. *Ann Chir Plast Esthet*. 2020 Jul;65(4):e1-e5.

Heudel P, Delalogue S, Parent D, Madranges N, Levy C, Dalenc F, Brain E, Uwer L, D'Hondt V, Augereau P, Mailliez A, Perrin C, Frenel JS, Sablin MP, Mouret-Reynier MA, Vermeulin T, Eymard JC, Petit T, Ferrero JM, Ilie S, Goncalves A, Chenuc G, Robain M, Simon G, Perol D. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study. *Anticancer Res*. 2020 Jul;40(7):3905-3913.

Fernandes R, Anton C, Lopes A, E Silva AS, Leblanc E, Ribeiro U Jr, Carvalho JP. Persistent postoperative ascites successfully identified and treated with laparoscopic indocyanine green fluorescence. *Int J Gynecol Cancer*. 2020 Aug;30(8):1250-1251.

Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, Pautier P, Angeles MA, Delanoy N, Lefeuvre-Plesse C, Cancel M, Treilleux I, Augereau P, Lavoue V, Kalbacher E, Berton Rigaud D, Selle F, Nadeau C, Gantzer J, Joly F, Guillemet C, Pomel C, Favier L, Abdeddaim C, Venat-Bouvet L, Provansal M, Fabbro M, Kaminsky MC, Lortholary A, Lecuru F, Coquard IR, de La Motte Rouge T. Need for risk-

adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network. *Gynecol Oncol.* 2020 Sep;158(3):666-672.

Robelin P, Tod M, Colomban O, Lachuer J, Ray-Coquard I, Rauglaudre G, Joly F, Chevalier-Place A, Combe P, Lortholary A, Hamizi S, Raban N, Ferron G, Meunier J, Berton-Rigaud D, Alexandre J, Kaminsky MC, Dubot C, Leary A, Malaurie E, You B. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). *Gynecol Oncol.* 2020 Oct;159(1):256-263.

Lanner M, Nikolova T, Gutic B, Nikolova N, Pletnev A, Selcuk I, Vlachos DE, Razumova Z, Bizzarri N, Theofanakis C, Lepka P, Kahramanoglu I, Han S, Nasser S, Molnar S, Hudry D, Montero-Macías R, de Lange N, Macuks R, Hasanov MF, Karimbayli R, Gagau I, Andrade C, Pardal C, Dotlic J, Alvarez RM, Hrudá M, Fruhauf F, Ekdahl L, Antonsen SL, Sukhin V, Eriksson AGZ, Gliozheni E, Delic R, Satanova A, Kovacevic N, Gristsenko L, Babloyan S, Zalewski K, Bharathan R. Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists. *Int J Gynecol Cancer.* 2020 Dec 24;ijgc-2020-002176.

Koual M, Hudry D, Nguyen-Xuan HT, Bentivegna E, Bats AS, Azaïs H. Comment je fais... pour initier les internes de gynécologie-obstétrique à la chirurgie robotique : mise en place d'un programme pédagogique de formation dans un service équipé du robot chirurgical [How I do... to train obstetrics and gynaecology residents in robotic surgery: Implementation of a pedagogical training program in a department equipped with the surgical robot]. *Gynecol Obstet Fertil Senol.* 2020 Nov 30;S2468-7189(20)30344-5.

Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, Gladiëff L, Lück HJ, Floquet A, Chevalier-Place A, Schnellzer A, Pignata S, Selle F, Sehouli J, Brocard F, Mangili G, Pautier P, De Giorgi U, Provansal M, Heudel PE. Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial. *JAMA Oncol.* 2020 Oct 8;6(12):1-9.

Simon V, Ngo C, Pujade-Lauraine E, Ferron G, Pomel C, Leblanc E, Nadeau C, Ray-Cocquard I, Lecuru F, Bonsang-Kitzis H. Should We Abandon Systematic Pelvic and Paraaortic Lymphadenectomy in Low-Grade Serous Ovarian Cancer? *Ann Surg Oncol.* 2020 Oct;27(10):3882-3890.

Lenck C, Chopin N, Gouy S, Bonsang-Kitzis H, Martinez-Gomez C, Radosevic-Robin N, Martin S, Lefeuvre-Plesse C, Lambaudie E, Leblanc E, Guyon F, Classe JM, Ramanah R, Beurrier F, Angeles MA, Pomel C, Joly F, de la Motte Rouge T, Provansal M, Lesoin A, Floquet A, Berton D, Kalbacher E, Chakiba C, Meeus P, Selle F, Treilleux I, Lecuru F, Pautier P, Ray-Coquard I. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study. *Gynecol Oncol.* 2020 Apr;157(1):78-84.

Sarcomes et Tumeurs rares (9 publications)

Dufresne A, Lesluyes T, Ménétrier-Caux C, Brahmi M, Darbo E, Toulmonde M, Italiano A, Mir O, Le Cesne A, Le Guellec S, Valentin T, Chevreau C, Bonvalot S, Robin YM, Coindre JM, Caux C, Blay JY, Chibon F. Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. *Oncoimmunology.* 2020 Jul 12;9(1):1792036.

Amadeo B, Penel N, Coindre JM, Ray-Coquard I, Ligier K, Delafosse P, Bouvier AM, Plouvier S, Gallet J, Lacourt A, Coureau G, Monnereau A, Mathoulin-Pélissier S, Desandes E. Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM). *BMC Cancer*. 2020 Mar 6;20(1):190.

Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2020 Mar;21(3):446-455.

Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Neron M, Sajous C, Thezenas S, Piperno-Neumann S, Reyat F, Laé M, Chakiba C, Penel N, Ryckewaert T, Honoré C, Bertucci F, Monneur A, Salas S, Duffaud F, Saada-Bouzid E, Isambert N, Brahmi M, Ray-Coquard I, Blay JY, Firmin N; French Sarcoma Group (GSF-GETO). Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. *Ann Surg Oncol*. 2020 May;27(5):1693-1699.

Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J. Pazopanib for treatment of advanced extraskelatal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2019 Sep;20(9):1252-1262.

Neron M, Sajous C, Thezenas S, Piperno-Neumann S, Reyat F, Laé M, Chakiba C, Michot A, Penel N, Honoré C, Owen C, Bertucci F, Salas S, Saada-Bouzid E, Valentin T, Bompas E, Brahmi M, Ray-Coquard I, Blay JY, Firmin N; French Sarcoma Group (GSF-GETO). Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. *Ann Surg Oncol*. 2020 Jun;27(6):1818-1827.

Pautier P, Penel N, Ray-Coquard I, Italiano A, Bompas E, Delcambre C, Bay JO, Bertucci F, Delaye J, Chevreau C, Cupissol D, Bozec L, Eymard JC, Saada E, Isambert N, Guillemet C, Rios M, Piperno-Neumann S, Chenuc G, Duffaud F. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). *Eur J Cancer*. 2020 Jan;125:31-37.

Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. *Eur J Cancer*. 2020 Mar;127:96-107.

Patrikidou A, Chaigneau L, Isambert N, Kitikidou K, Shanley R, Ray-Coquard I, Valentin T, Malivoir B, Laigre M, Bay JO, Moureau-Zabotto L, Bompas E, Piperno-Neumann S, Penel N, Alcindor T, Guillemet C, Duffaud F, Hügli A, Le Pechoux C, Dhermain F, Blay JY, Sperduto PW, Le Cesne A. Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). *BMC Cancer*. 2020 Feb 12;20(1):117.

VADS (7 publications)

Podeur F, Pommier P, Crozes C, Monchet E, Ton Van J, Roux PE, Poupart M, Zrounba P, Julieron M, Deneuve S. Management of unilateral head and neck carcinoma of unknown primary: Retrospective analysis of the impact of postoperative radiotherapy target volumes. *Head Neck*. 2020 Feb;42(2):302-311.

Dahan LS, Giorgi R, Vergez S, Le Taillandier de Gabory L, Costes-Martineau V, Herman P, Poissonnet G, Mauvais O, Malard O, Garrel R, Uro-Coste E, Barry B, Bach C, Chevalier D, Mouawad F, Merol JC, Bastit V, Thariat J, Gilain L, Dufour X, Righini CA, Moya-Plana A, Even C, Radulesco T, Michel J, Baujat B, Fakhry N; REFCOR members. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases. *Eur J Surg Oncol*. 2020 Nov 21:S0748-7983(20)31019-2.

Villa S, Druelle C, Juliéron M, Nicot R. Reconstruction mandibulaire par lambeau fibulaire : note technique de pré-conformation de plaques d'ostéosynthèse assistée en 3D [3D-assisted mandibular reconstruction: A technical note of fibula free flap with preshaped titanium plate]. *Ann Chir Plast Esthet*. 2020 Aug 1:S0294-1260(20)30098-4.

Marti-Flich L, Schlund M, Raoul G, Maes JM, Ferri J, Wojcik T, Nicot R. Twenty-four years of experience in management of complex mandibular fractures with low cost, custom-made mandibular external fixation: A 65-patient series. *J Stomatol Oral Maxillofac Surg*. 2020 Jun;121(3):242-247.

Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. *Lung Cancer*. 2020 Jan;139:22-27.

Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C; Groupe Français de Pneumo-Cancérologie 01–13 investigators. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2020 Sep;21(9):1224-1233.

Gobbini E, Toffart AC, Pérol M, Assié JB, Duruisseaux M, Coupeze D, Dubos C, Westeel V, Delaunay M, Guisier F, Veillon R, Gounant V, Giroux Leprieur E, Vanel FR, Chaabane N, Dansin E, Babey H, Decroisette C, Barlesi F, Daniel C, Fournel P, Mezquita L, Oulkhair Y, Canellas A, Duchemann B, Molinier O, Alcazer V, Moro-Sibilot D, Levra MG. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. *Clin Lung Cancer*. 2020 Sep;21(5):e497-e510.

Soins palliatifs (1 publication)

Bouleuc C, Anota A, Cornet C, Grodard G, Thiery-Vuillemin A, Dubroeuq O, Créteineau N, Frasier V, Gambin V, Chvetzoff G, Favier L, Tournigand C, Grach MC, Raynard B, Salas S, Capodano G, Pazart L, Aubry R. Impact on Health-Related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: Results from a Randomized Controlled Trial. *Oncologist*. 2020 May;25(5):e843-e851.

Autres publications

Bayar MA, Le Teuff G, Koenig F, Le Deley MC, Michiels S. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. *Stat Methods Med Res.* 2020 Jun;29(6):1483-1498.

Marcant P, Moreau A, Da Silva A, Aelbrecht-Meurisse C, Staumont-Sallé D. Central venous access device-associated contact dermatitis in patients with cancer: The utility of extensive screening patch tests. *Contact Dermatitis.* 2020 Nov 19.

Gehenne L, Christophe V, Eveno C, Carnot A, Turpin A, Pannier D, Piessen G, Lelorain S. Creating scripted video-vignettes in an experimental study on two empathic processes in oncology: Reflections on our experience. *Patient Educ Couns.* 2020 Sep 6:S0738-3991(20)30472-9.

Timsit JF, Baleine J, Bernard L, Calvino-Gunther S, Darmon M, Dellamonica J, Desruennes E, Leone M, Lepape A, Leroy O, Lucet JC, Merchaoui Z, Mimoz O, Misset B, Parienti JJ, Quenot JP, Roch A, Schmidt M, Slama M, Souweine B, Zahar JR, Zingg W, Bodet-Contentin L, Maxime V. Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit. *Ann Intensive Care.* 2020 Sep 7;10(1):118.

Haaser T, Constantinidès Y, Dejean C, Escande A, Le Tallec P, Lorchel F, Marty S, Thureau S, Huguet F, Lagrange JL; pour la Commission éthique de la SFRO. Démocratie sanitaire : le patient partenaire de sa prise en charge [Health democracy: Patient partnership]. *Cancer Radiother.* 2020 Oct;24(6-7):736-743.

Tubeuf H, Caputo SM, Sullivan T, Rondeaux J, Krieger S, Caux-Moncoutier V, Hauchard J, Castelain G, Fiévet A, Meulemans L, Révillion F, Léoné M, Boutry-Kryza N, Delnatte C, Guillaud-Bataille M, Cleveland L, Reid S, Southon E, Soukarieh O, Drouet A, Di Giacomo D, Vezain M, Bonnet-Dorion F, Bourdon V, Larbre H, Muller D, Pujol P, Vaz F, Audebert-Bellanger S, Colas C, Venat-Bouvet L, Solano AR, Stoppa-Lyonnet D, Houdayer C, Frebourg T, Gaildrat P, Sharan SK, Martins A. Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using *BRCA2* Exon 3 as a Model System. *Cancer Res.* 2020 Sep 1;80(17):3593-3605.

Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, Thomas-Schoemann A, Chevrier R, Daouphars M, Madelaine I, Pourroy B, Tournamille JF, Astier A, Ranchon F, Cazin JL, Bardin C, Rioufol C. Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). *Cancer Treat Rev.* 2020 Aug;88:102063.

Peperstraete E, Lecerf C, Collette J, Vennin C, Raby L, Völkel P, Angrand PO, Winter M, Bertucci F, Finetti P, Lagadec C, Meignan S, Bourette RP, Bourhis XL, Adriaenssens E. Enhancement of Breast Cancer Cell Aggressiveness by lncRNA *H19* and its Mir-675 Derivative: Insight into Shared and Different Actions. *Cancers (Basel).* 2020 Jun 29;12(7):1730.

Dinart D, Fraisse J, Tosi D, Mauguen A, Touraine C, Gourgou S, Le Deley MC, Bellera C, Mollevi C. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials. *BMC Med Inform Decis Mak.* 2020 Jun 24;20(1):134.

Belkacemi Y, Grellier N, Ghith S, Debbi K, Coraggio G, Bounedjar A, Samlali R, Tsoutsou PG, Ozsahin M, Chauvet MP, Turkan S, Boussem H, Kuten A, Tesanovic D, Errihani H, Benna F, Bouzid K, Idbaih A,

Mokhtari K, Popovic L, Spano JP, Lotz JP, Cherif A, To H, Kovcin V, Arsovski O, Beslija S, Dzodic R, Markovic I, Vasovic S, Stamatovic L, Radosavljevic D, Radulovic S, Vrbanec D, Sahraoui S, Vasev N, Stojkovski I, Risteski M, Freixa SV, Krengli M, Radosevic N, Mustacchi G, Filipovic M, Kerrou K, Taghian AG, Todorovic V, Geara F, Gligorov J. A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. *Eur J Cancer*. 2020 Aug;135:130-146.

Deligne C, Hachani J, Duban-Deweere S, Meignan S, Leblond P, Carcaboso AM, Sano Y, Shimizu F, Kanda T, Gosselet F, Dehouck MP, Mysiorek C. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. *Fluids Barriers CNS*. 2020 Jun 2;17(1):37.

Fontaine-Delaruelle C, Mazières J, Cadranet J, Mastroianni B, Dubos-Arvis C, Dumont P, Monnet I, Pichon E, Locatelli-Sanchez M, Dixmier A, Coudert B, Fraboulet S, Foucher P, Dansin E, Baize N, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S; IFCT10-02 BioCAST investigators. Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study. *Respir Med Res*. 2020 Mar;77:58-66.

Perez-Gracia JL, Awada A, Calvo E, Amaral T, Arkenau HT, Gruenwald V, Bodoky G, Lolkema MP, Di Nicola M, Penel N, Vera R, Sanmamed MF, Douillard JY. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. *ESMO Open*. 2020 May;5(3):e000662.

Scanvion Q, Béné J, Gautier S, Grandvullemin A, Le Beller C, Chenaf C, Etienne N, Brousseau S, Cortot AB, Mortier L, Staumont-Sallé D, Morschhauser F, Forestier A, Groh M, Launay D, Hachulla E, Labalette M, Kahn JE, Lefèvre G. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. *Oncoimmunology*. 2020 Apr 7;9(1):1722022.

Magné N, Sabatier R, Wislez M, André T, Rodrigues M, Hervé L, Thiery-Vuillemin A, Penel N, Bouleuc C, Bay JO. Florilège des actualités oncologiques internationales en 2019 [2019 international oncology news: A compendium]. *Bull Cancer*. 2020 Feb;107(2):148-156.

Meulemans L, Mesman RLS, Caputo SM, Krieger S, Guillaud-Bataille M, Caux-Moncoutier V, Léone M, Boutry-Kryza N, Sokolowska J, Révillion F, Delnatte C, Tubeuf H, Soukarieh O, Bonnet-Dorion F, Guibert V, Bronner M, Bourdon V, Lizard S, Vilquin P, Privat M, Drouet A, Grout C, Calléja FMGR, Golmard L, Vrieling H, Stoppa-Lyonnet D, Houdayer C, Frebourg T, Vreeswijk MPG, Martins A, Gaildrat P. Skipping Nonsense to Maintain Function: The Paradigm of *BRCA2* Exon 12. *Cancer Res*. 2020 Apr 1;80(7):1374-1386.

Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghousaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Aronson KJ, Arun BK, Auber B, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Beeghly-Fadiel A, Benitez J, Bermisheva M, Białkowska K, Blanco AM, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Bosse K, Brauch H, Brenner H, Briceno I, Brock IW, Brooks-Wilson A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldés T, Caligo MA, Camp NJ, Campbell I, Canzian F, Carroll JS, Carter BD, Castelao JE, Chiquette J, Christiansen H, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators;

EMBRACE Collaborators, Collée JM, Cornelissen S, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Domchek SM, Dörk T, Dos-Santos-Silva I, Droit A, Dubois S, Dumont M, Duran M, Durcan L, Dwek M, Eccles DM, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Floris G, Flyger H, Foretova L, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gago-Dominguez M, Gambino G, Ganz PA, Gapstur SM, Garber J, García-Sáenz JA, Gaudet MM, Georgoulas V, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Tibiletti MG, Greene MH, Grip M, Gronwald J, Grundy A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hartikainen JM, Hartman M, He W, Healey CS, Heemskerk-Gerritsen BAM, Heyworth J, Hillemanns P, Hogervorst FBL, Hollestelle A, Hooning MJ, Hopper JL, Howell A, Huang G, Hulick PJ, Imyanitov EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators, Isaacs C, Iwasaki M, Jager A, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kang D, Kapoor PM, Karlan BY, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Kirk J, Kitahara CM, Ko YD, Konstantopoulou I, Kosma VM, Koutros S, Kubelka-Sabit K, Kwong A, Kyriacou K, Laitman Y, Lambrechts D, Lee E, Leslie G, Lester J, Lesueur F, Lindblom A, Lo WY, Long J, Lophatananon A, Loud JT, Lubiński J, MacInnis RJ, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matsuo K, Maurer T, Mavroudis D, Mayes R, McGuffog L, McLean C, Mebirouk N, Meindl A, Miller A, Miller N, Montagna M, Moreno F, Muir K, Mulligan AM, Muñoz-Garzon VM, Muranen TA, Narod SA, Nassir R, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nikitina-Zake L, Norman A, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Osorio A, Pankratz VS, Papp J, Park SK, Park-Simon TW, Parsons MT, Paul J, Pedersen IS, Peissel B, Peshkin B, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prajzandanc K, Prentice R, Presneau N, Prokofyeva D, Pujana MA, Pykäs K, Radice P, Ramus SJ, Rantala J, Rau-Murthy R, Rennert G, Risch HA, Robson M, Romero A, Rossing M, Saloustros E, Sánchez-Herrero E, Sandler DP, Santamariña M, Saunders C, Sawyer EJ, Scheuner MT, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Scott C, Scott RJ, Senter L, Seynaeve CM, Shah M, Sharma P, Shen CY, Shu XO, Singer CF, Slavin TP, Smichkoska S, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Stoppa-Lyonnet D, Sutter C, Swerdlow AJ, Tamimi RM, Tan YY, Tapper WJ, Taylor JA, Teixeira MR, Tengström M, Teo SH, Terry MB, Teulé A, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Torres-Mejía G, Troester MA, Truong T, Tung N, Tzardi M, Ulmer HU, Vachon CM, van Asperen CJ, van der Kolk LE, van Rensburg EJ, Vega A, Viel A, Vijai J, Vogel MJ, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wildiers H, Winqvist R, Wolk A, Wu AH, Yannoukakos D, Zhang Y, Zheng W, Hunter D, Pharoah PDP, Chang-Claude J, García-Closas M, Schmidt MK, Milne RL, Kristensen VN, French JD, Edwards SL, Antoniou AC, Chenevix-Trench G, Simard J, Easton DF, Kraft P, Dunning AM. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nat Genet.* 2020 Jan;52(1):56-73.